Literature DB >> 2339700

Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the alpha 1(I) gene (COL1A1) of type I collagen in a parent.

G A Wallis1, B J Starman, A B Zinn, P H Byers.   

Abstract

Fibroblasts from a man with a mild form of osteogenesis imperfecta (OI) and from his son with perinatal lethal OI (OI type II) produced normal and abnormal type I procollagen molecules. The abnormal molecules synthesized by both cell strains contained one or two pro alpha 1(I) chains in which the glycine at position 550 of the triple-helical domain was substituted by arginine as the result of a G-to-A transition in the first base of the glycine codon. Cells from the mother produced only normal type I procollagen molecules. By allele-specific oligonucleotide hybridization to amplified genomic sequences from paternal tissues we determined that the mutant allele accounted for approximately 50% of the COL1A1 alleles in fibroblasts, 27% of those in blood, and 37% of those in sperm. These findings demonstrate that the father is mosaic for the potentially lethal mutation and suggest that the OI phenotype is determined by the nature of the mutation and the relative abundance of the normal and mutant alleles in different tissues. Furthermore, the findings make it clear that some individuals with mild to moderate forms of OI are mosaic for mutations that will be lethal in their offspring.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339700      PMCID: PMC1683813     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  16 in total

1.  Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the alpha 1(I) chain of type I collagen.

Authors:  J F Bateman; D Chan; I D Walker; J G Rogers; W G Cole
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

2.  Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen.

Authors:  P H Byers; P Tsipouras; J F Bonadio; B J Starman; R C Schwartz
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

3.  Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta.

Authors:  J Bonadio; K A Holbrook; R E Gelinas; J Jacob; P H Byers
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

6.  Analysis of the heterogeneity of human collagens by two-dimensional polyacrylamide-gel electrophoresis.

Authors:  W G Cole; D Chan
Journal:  Biochem J       Date:  1981-08-01       Impact factor: 3.857

7.  Two-dimensional CNBr peptide patterns of collagen types I, II and III.

Authors:  P D Benya
Journal:  Coll Relat Res       Date:  1981

8.  Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I.

Authors:  M C Willing; D H Cohn; P H Byers
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

9.  A system for shotgun DNA sequencing.

Authors:  J Messing; R Crea; P H Seeburg
Journal:  Nucleic Acids Res       Date:  1981-01-24       Impact factor: 16.971

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  45 in total

1.  A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta.

Authors:  J Bonaventure; L Cohen-Solal; C Lasselin; P Maroteaux
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

2.  Substitution of aspartate for glycine 1018 in the type III procollagen (COL3A1) gene causes type IV Ehlers-Danlos syndrome: the mutated allele is present in most blood leukocytes of the asymptomatic and mosaic mother.

Authors:  S Kontusaari; G Tromp; H Kuivaniemi; C Stolle; F M Pope; D J Prockop
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

3.  Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen.

Authors:  C J Pruchno; D H Cohn; G A Wallis; M C Willing; B J Starman; X M Zhang; P H Byers
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

4.  A mutation causing Alport syndrome with tardive hearing loss is common in the western United States.

Authors:  D F Barker; C J Pruchno; X Jiang; C L Atkin; E M Stone; J C Denison; P R Fain; M C Gregory
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

Review 5.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

6.  Germinal mosaicism and risk calculation in X-linked diseases.

Authors:  M Jeanpierre
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

Review 7.  Perinatal lethal osteogenesis imperfecta.

Authors:  W G Cole; R Dalgleish
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

8.  Kniest dysplasia is caused by dominant collagen II (COL2A1) mutations: parental somatic mosaicism manifesting as Stickler phenotype and mild spondyloepiphyseal dysplasia.

Authors:  J Spranger; H Menger; S Mundlos; A Winterpacht; B Zabel
Journal:  Pediatr Radiol       Date:  1994

9.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

10.  Somatic mosaicism in a patient with neurofibromatosis type 1.

Authors:  S D Colman; S A Rasmussen; V T Ho; C R Abernathy; M R Wallace
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.